Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Open access
Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.·2011·Blood

Abstract

Multiple myeloma (MM) patients who receive killer cell Ig–like receptor (KIR) ligand–mismatched, T cell–depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligand–matched grafts, suggesting the importance of this signaling axis in the natural killer (NK) cell-versus-MM effect. Expanding on this concept, IPH2101 (1-7F9), an anti-inhibitory KIR mAb, enhances NK-cell function against autologous MM cells by blocking the engagement of inhibitory KIR with cognate ligands, promoting immune complex formation and NK-cell cytotoxicity specifically against MM cell targets but not normal cells. IPH2101 prevents negative regulatory signals by inhibitory KIR, whereas lenalidomide augments NK-cell function and also appears to up-regulate ligands for activating NK-cell receptors on MM cells. Lenalidomide and a murine anti-inhibitory NK-cell receptor Ab mediate in vivo rejection of a lenalidomide-resistant tumor. These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-06-360255

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 208

Metadata

Authors
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., Bléry, M., Bonnafous, C., Zhang, J., Clever, D., Caligiuri, M. A., & Farag, S. S.
Venue
Blood
Published
2011-12-08
Volume
118
Issue
24
Pages
6387-6391
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2090083883
Cited by
208
References
4
FWCI
6.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. https://app.cochat.ai/papers/10.1182/blood-2011-06-360255
The paper
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., Bléry, M., Bonnafous, C., Zhang, J., Clever, D., Caligiuri, M. A., & Farag, S. S. (2011). IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. https://doi.org/10.1182/blood-2011-06-360255

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.